RecruitingPhase 4NCT06792214

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD (DEFEND) Clinical Trial

Sponsor

Mount Sinai Hospital, Canada

Enrollment

118 participants

Start Date

Jan 3, 2025

Study Type

INTERVENTIONAL

Conditions

SARS CoV-2 Post-Acute Sequelae

Summary

The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Nirmatrelvir/ritonavir and a drug called Remdesivir for people with sars cov-2 post-acute sequelae. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNirmatrelvir/ritonavir

Paxlovid PO BID for 5 days + standard of care

DRUGRemdesivir

Veklury IV daily for 5 days + standard of care

Locations(4)

Kingston Health Sciences Centre

Kingston, Ontario, Canada

Niagara Health System

St. Catharines, Ontario, Canada

Mount Sinai Hospital, Sinai Health System

Toronto, Ontario, Canada

St. Joseph's Health Centre, Unity Health Toronto

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06792214

Related Trials

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

NCT056561051 location